Skip to search formSkip to main contentSkip to account menu

SB-485232

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Recombinant Interleukin-18

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Chemo-immunotherapy Using Pegylated Liposomal Doxorubicin and Interleukin-18 in Recurrent Ovarian Cancer : a Phase I Dose-escalation Study
Review
2005
Review
2005
Technology evaluation: SB-485232, GlaxoSmithKline.
GlaxoSmithKline (formerly SmithKline Beecham), under license from Hayashibara, is developing SB-485232, a recombinant human… 
2004
2004
Tolerability and anti-tumor activity of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions in patients with solid tumors.
2553 Background: rhIL-18, a member of the Th-1 inducing family of cytokines, has demonstrated anti-tumor activity in a variety of… 
2004
2004
Phase I dose escalation study to assess tolerability and pharmacokinetics of recombinant human IL-18 (rhIL-18) administered as fourteen daily subcutaneous injections in patients with solid tumors.
2591 Background: Tolerability of rhIL-18 (SB485232) administered intravenously on 5 consecutive days was reported previously… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)